BioSpace News Archive

Axonics Modulation Technologies, Inc. announced that it has entered into an agreement to supply the Axonics r-SNM® System to The University of Tennessee Medical Center in Knoxville, Tennessee.

Aerie Pharmaceuticals, Inc. announced the European Commission has granted a marketing authorisation for Rhokiinsa® 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.

MEDNAX Radiology Solutions, one of the nation’s leading radiology practices, and Virtual Radiologic, a MEDNAX company, will exhibit at the Radiological Society of North America’s 2019 Annual Meeting from Dec. 1-6 at McCormick Place in Chicago.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced that Karen Zaderej, chairman, CEO, and president, will present at the Piper Jaffray 31st Annual Healthcare Conference in New York City.

41 percent objective response rate (ORR) as assessed by the investigator in 42 patients who were primary refractory to anti-PD-1/L1 therapy

Molecular Templates, Inc. announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $8.00 per share and 250 shares of its newly designated Series A convertible preferred stock at a public offering price of $8,000 per share.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, is hosting an R&D conference call and webcast with slides on Monday, November 25, 2019 at 9:00 AM Eastern Time with key opinion leaders focusing on AXS-07 and the unmet needs in the acute treatment of migraine.

Daxor Corporation(NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces new data from The Yale University School of Medicine that was presented on November 16th at the American Heart Association Scientific Sessions in Philadelphia, PA.

Silk Medical Aesthetics, a spin-off of green chemistry company Evolved By Nature, today announced it has finished enrollment in a clinical trial for the dermatology industry’s first silk-based dermal filler

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced new positive results on drug distribution from the recently completed Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma (“rGBM”), the most common and uniformly fatal form of brain cancer.